Further analysis revealed that the expression levels of CD103 and CD83 on cDC1 in the Neo-BCV group were significantly higher than in the PBS group, indicating that the DCs in the Neo-BCV group have stronger antigen presentation ability, laying the foundation for an anti-tumor response. This evidence concerns the gene CD83 and neoplasm.